Skip to main content
SpringerLink
Log in

Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease

  • Letter to the Editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Fisher E, Brinar VV, Giovannoni G, Stojanovic M, Ertik BI, Lake SL, Margolin DH, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomized controlled phase 3 trial. Lancet 380:1819–1828

    Article  CAS  Google Scholar 

  2. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, Hartung HP, Havrdova E, Selmaj KW, Weiner HL, Miller T, Fisher E, Sandbrink R, Lake SL, Margolin DH, Oyuela P, Panzara MA, Compston DA (2012) Investigators C-MI. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 380:1829–1839

    Article  CAS  Google Scholar 

  3. Havrdova E, Horakova D, Kovarova I (2015) Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord 8:31–45

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Coles AJ, Cohen JA, Fox EJ, Giovannoni G, Hartung HP, Havrdova E, Schippling S, Selmaj KW, Traboulsee A, Compston DAS, Margolin DH, Thangavelu K, Chirieac MC, Jody D, Xenopoulos P, Hogan RJ, Panzara MA, Arnold DL (2017) Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. Neurology 89:1117–1126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Malmeström C, Andersson BA, Lycke J (2014) First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol 261:2016–2018

    Article  PubMed  Google Scholar 

  6. Wertman E, Zilber N, Abramsky O (1992) An association between multiple sclerosis and type I diabetes mellitus. J Neurol 239:43–45

    Article  CAS  PubMed  Google Scholar 

  7. Marrosu MG, Cocco E, Lai M, Spinicci G, Pischedda MP, Contu P (2002) Patients with multiple sclerosis and risk of type 1 diabetes mellitus in Sardinia, Italy: a cohort study. Lancet 359:1461–1465

    Article  PubMed  Google Scholar 

  8. Hussein WI, Reddy SS (2006) Prevalence of diabetes in patients with multiple sclerosis. Diabetes Care 29:1984–1985

    Article  PubMed  Google Scholar 

  9. Ruck T, Pfeuffer S, Schulte-Mecklenbeck A, Gross CC, Lindner M, Metze D, Ehrchen J, Sondermann W, Pul R, Kleinschnitz C, Wiendl H, Meuth MD, Klotz SG (2018) L. Vitiligo after alemtuzumab treatment, Secondary autoimmunity is not all about B cells. Neurology 91:e2233–e2237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Della Valle P, Coluccia A, Martinelli V, Comi G, D´Angelo A, Moiola L (2018) Acquired haemophilia a as a secondary autoimmune disease after alemtuzumab treatment in multiple sclerosis: a case report. Mult Scler Relat Disord 27:403–405

    PubMed  Google Scholar 

  11. Hoffman BM, Zeid NA, Alam U, Caress JB (2019) Lambert-Eaton myasthenic syndrome associated with alemtuzumab administration. Mult Scler Relat Disord 27:131–132

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neuro-MVZ (MIND) Stuttgart, Charlottenstrasse 14, 70182, Stuttgart, Germany

    Stephan Richter & Bert Wagner

  2. Department of Neurology, Oslo University Hospital, 4956, 0424, Ullevål, Boks, Nydalen, Oslo, Norway

    Elisabeth Gulowsen Celius

  3. Institute of Clinical Medicine, University of Oslo, Oslo, Norway

    Elisabeth Gulowsen Celius

Authors
  1. Stephan Richter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bert Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Elisabeth Gulowsen Celius
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Richter.

Ethics declarations

Conflicts of interest

Stephan Richter has received honoraria for advisory board councils and travel expenses for attending meetings from Biogen, Celgene, Genzyme, Merck, Novartis and Roche. Bert Wagner has received honoraria for advisory board councils and travel expenses for attending meetings from Biogen, Genzyme, Merck, Novartis and Roche. Elisabeth G. Celius has received honoraria for advisory boards and/or speaker honoraria from Biogen, Merck, Roche, Novartis, Genzyme and Teva, and unrestricted research grants from Novartis and Genzyme.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Richter, S., Wagner, B. & Celius, E.G. Two cases of diabetes mellitus type 1 after alemtuzumab treatment for multiple sclerosis: another probable secondary autoimmune disease. J Neurol 266, 1270–1271 (2019). https://doi.org/10.1007/s00415-019-09257-5

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-019-09257-5

Search

Navigation